Epigenomics AG. (7/2/18). "Press Release: Liquid Biopsy Test for Liver Cancer Detection to Obtain CE Mark". Berlin & San Diego, CA.

	Region	EU (European Union)
	Organisation	Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
	Group	Epigenomics (Group)
	Organisation 2	FDA (US Food and Drug Administration)
	Group	United States (govt)
	Product	SEPT9 DNA Methylation Biomarker (mSEPT9)
	Product 2	cancer test, early detection
	Person	Hamilton, Gregory (Greg) (Epigenomics 201607– CEO before AltheaDx + Enigma Diagnostics + Third Wave + Hologic)
	Person 2	Vogt, Peter (Epigenomics 201601 Investor + Public Relations)

- Epigenomics plans to CE Mark mSEPT9 blood test for liver cancer by year-end 2018, enabling commercialization in Europe

- Prospective U.S. trial for FDA submission to be initiated in 2019

- Investigating optimal path for CFDA approval in China

Epigenomics AG (FSE: ECX, OTCQX: EPGNY) today announced it’s plan to CE Mark mSEPT9 blood test by year-end 2018 to aid in detecting liver cancer among patients with cirrhosis. In 2019, the company also plans to initiate a prospective clinical trial in the U.S. for submission to the FDA. Additionally, Epigenomics is evaluating options to expedite CFDA approval in China.

In a recently reported clinical study, the mSEPT9 blood test demonstrated high sensitivity of 90.6 percent at a specificity of 87.2 percent for the indication of liver cancer. Furthermore, the mSEPT9 blood test exhibited higher diagnostic accuracy compared to alpha-fetoprotein (AFP), a widely used serum diagnostic marker for liver cancer.

According to the World Health Organization (WHO), liver cancer is the second most common cause of death from cancer worldwide with Hepatocellular carcinoma (HCC) accounting for 70-90 percent of primary liver cancers (PLC)*. A major risk-factor for developing HCC is liver cirrhosis. Globally, Epigenomics estimates the liver cirrhosis surveillance market to be in excess of 10 million tests per year making it more than a three billion Euro market opportunity globally.

In Europe, liver cirrhosis is responsible for over 170,000 deaths per year* and Epigenomics estimates approximately three million patients per year in Western Europe are eligible for liver surveillance resulting in a total available market of over one billion Euros per year. Epigenomics is currently evaluating the best potential commercial partnership opportunities for the distribution of the product.

“We are very excited about the opportunity to launch the first liquid biopsy test for liver cancer”, said Greg Hamilton, CEO of Epigenomics AG. “Based on the initial performance data of the test, we are moving forward with CE Marking and prospective clinical studies to capitalize on the opportunity to address this deadly disease.”

*Journal of Hepatology Volume 58, Issue 3 March 2013, Blachier et.al.

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon®, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung®, a blood-based test for lung cancer detection, has received CE mark in Europe.

For more information, visit www.epigenomics.com.

Contact:
Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: ir@epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Record changed: 2018-08-14